- Home
- AMBP vs AUPH Comparison
AMBP vs AUPH Comparison
Compare AMBP & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMBP | AUPH |
|---|---|---|
| Founded | 2021 | 1993 |
| Country | Luxembourg | Canada |
| Employees | 6500 | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMBP | AUPH |
|---|---|---|
| Price | $4.80 | $15.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $4.39 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 10.39% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $7.31 | $17.54 |
| Revenue Next Year | $2.53 | $15.74 |
| P/E Ratio | ★ N/A | $62.44 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $3.29 | $7.36 |
| 52 Week High | $5.03 | $19.25 |
Technical Indicators
Market Signals| Indicator | AMBP | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 74.97 | 42.95 |
| Support Level | $3.90 | $15.55 |
| Resistance Level | $5.00 | $16.07 |
| Average True Range (ATR) | 0.16 | 0.84 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 98.04 | 10.34 |
Price Performance
Historical ComparisonAbout AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. The geographical segments of the company includes Europe and the Americas. Geographically, the company derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.